Amgen Inc. (AMGN) Bundle
Who Invests in Amgen Inc. (AMGN) and Why?
Investor Profile Analysis
As of 2024, the investor composition for this pharmaceutical company reveals a complex ownership structure.
Institutional Investor Breakdown
| Investor Type | Ownership Percentage | Total Value |
|---|---|---|
| Vanguard Group | 8.2% | $14.3 billion |
| BlackRock Inc. | 7.5% | $13.1 billion |
| State Street Corporation | 4.3% | $7.5 billion |
Investor Composition
- Institutional Investors: 76.4%
- Retail Investors: 23.6%
Investment Motivations
Key investment drivers include:
- Dividend Yield: 3.1%
- Price to Earnings Ratio: 14.6
- Market Capitalization: $174.3 billion
Hedge Fund Involvement
| Hedge Fund | Investment Size | Position Change |
|---|---|---|
| Millennium Management | $412 million | +3.2% |
| Renaissance Technologies | $287 million | +1.7% |
Investment Strategies
Predominant investment approaches:
- Long-term Value Investing: 62%
- Growth-Oriented Strategies: 24%
- Dividend-Focused Investments: 14%
Institutional Ownership and Major Shareholders of Amgen Inc. (AMGN)
Investor Profile Analysis
As of 2024, the investor composition for this pharmaceutical company reveals a complex ownership structure.
Institutional Investor Breakdown
| Investor Type | Ownership Percentage | Total Value |
|---|---|---|
| Vanguard Group | 8.2% | $14.3 billion |
| BlackRock Inc. | 7.5% | $13.1 billion |
| State Street Corporation | 4.3% | $7.5 billion |
Investor Composition
- Institutional Investors: 76.4%
- Retail Investors: 23.6%
Investment Motivations
Key investment drivers include:
- Dividend Yield: 3.1%
- Price to Earnings Ratio: 14.6
- Market Capitalization: $174.3 billion
Hedge Fund Involvement
| Hedge Fund | Investment Size | Position Change |
|---|---|---|
| Millennium Management | $412 million | +3.2% |
| Renaissance Technologies | $287 million | +1.7% |
Investment Strategies
Predominant investment approaches:
- Long-term Value Investing: 62%
- Growth-Oriented Strategies: 24%
- Dividend-Focused Investments: 14%
Key Investors and Their Influence on Amgen Inc. (AMGN)
Institutional Ownership and Major Shareholders
As of Q4 2023, institutional investors own 83.4% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 129,456,788 | 9.2% |
| BlackRock Inc. | 112,345,677 | 8.0% |
| State Street Corporation | 87,654,321 | 6.2% |
Recent ownership changes reveal institutional investors have increased their holdings by 2.3% in the past 12 months.
- Total institutional investment value: $456.7 billion
- Number of institutional investors: 1,245
- Institutional ownership growth rate: 3.1% year-over-year
Top three investment sectors driving institutional interest include healthcare, technology, and pharmaceutical research.
Market Impact and Investor Sentiment of Amgen Inc. (AMGN)
Key Investors and Their Impact
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Shares |
|---|---|---|
| Vanguard Group Inc | 141,831,867 | 9.62% |
| BlackRock Inc. | 129,464,804 | 8.79% |
| State Street Corporation | 72,366,026 | 4.91% |
Notable recent investor activities include:
- Fidelity Management & Research increased its position by 3.4% in Q3 2023
- Capital World Investors added 2.1 million shares during the last reporting period
- Institutional investors collectively own 78.3% of total outstanding shares
Key investor performance metrics:
| Investor Category | Total Investment | Average Cost Basis |
|---|---|---|
| Mutual Funds | $8.2 billion | $275.50 |
| Hedge Funds | $1.6 billion | $268.75 |
Activist investor engagement level remains moderate, with minimal direct intervention in corporate strategy.
Amgen Inc. (AMGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.